To further demonstrate that knockdown of LFPRLR could be therapeutically beneficial by inhibiting progression of overt B-cell malignancies, we tested the efficacy of LFPRLR SMO in the clearance of two human DLBCL cell-line derived xenografts (CDX) transplanted into immune-deficient NOD-SCID IL2Rγ−/− (NSG) mice. The gene discussed is IL2RG; the disease is diffuse large B-cell lymphoma.